Response after induction, after HDM, and after consolidation by carfilzomib dosing level and risk status
| . | Dosing level of carfilzomib . | Risk status by cytogenetics and ISS stage . | ||||
|---|---|---|---|---|---|---|
| 20/27 mg/m2 . | 20/36 mg/m2 . | 20/45 mg/m2 . | All patients . | Standard risk* . | High risk* . | |
| Patients, n | 50 | 20 | 21 | 91 | 36 | 35 |
| Response after induction, n (%) | ||||||
| CR | 10 (20) | 6 (30) | 7 (33) | 23 (25) | 3 (8) | 9 (26) |
| ≥VGPR | 28 (56) | 17 (85) | 17 (81) | 62 (68) | 25 (69) | 22 (63) |
| ≥PR | 46 (92) | 18 (90) | 18 (86) | 82 (90) | 34 (94) | 32 (91) |
| Response after HDM, n (%) | ||||||
| CR | 14 (28) | 8 (40) | 8 (38) | 30 (33) | 9 (25) | 14 (40) |
| ≥VGPR | 32 (64) | 18 (90) | 19 (90) | 69 (76) | 29 (81) | 25 (71) |
| ≥PR | 47 (94) | 20 (100) | 20 (95) | 87 (96) | 34 (94) | 33 (94) |
| Response after consolidation, n (%) | ||||||
| CR | 29 (58) | 14 (70) | 14 (67) | 57 (63) | 21 (58) | 23 (66) |
| ≥VGPR | 43 (86) | 18 (90) | 20 (95) | 81 (89) | 31 (86) | 30 (86) |
| ≥PR | 47 (94) | 20 (100) | 20 (95) | 87 (96) | 34 (94) | 33 (94) |
| . | Dosing level of carfilzomib . | Risk status by cytogenetics and ISS stage . | ||||
|---|---|---|---|---|---|---|
| 20/27 mg/m2 . | 20/36 mg/m2 . | 20/45 mg/m2 . | All patients . | Standard risk* . | High risk* . | |
| Patients, n | 50 | 20 | 21 | 91 | 36 | 35 |
| Response after induction, n (%) | ||||||
| CR | 10 (20) | 6 (30) | 7 (33) | 23 (25) | 3 (8) | 9 (26) |
| ≥VGPR | 28 (56) | 17 (85) | 17 (81) | 62 (68) | 25 (69) | 22 (63) |
| ≥PR | 46 (92) | 18 (90) | 18 (86) | 82 (90) | 34 (94) | 32 (91) |
| Response after HDM, n (%) | ||||||
| CR | 14 (28) | 8 (40) | 8 (38) | 30 (33) | 9 (25) | 14 (40) |
| ≥VGPR | 32 (64) | 18 (90) | 19 (90) | 69 (76) | 29 (81) | 25 (71) |
| ≥PR | 47 (94) | 20 (100) | 20 (95) | 87 (96) | 34 (94) | 33 (94) |
| Response after consolidation, n (%) | ||||||
| CR | 29 (58) | 14 (70) | 14 (67) | 57 (63) | 21 (58) | 23 (66) |
| ≥VGPR | 43 (86) | 18 (90) | 20 (95) | 81 (89) | 31 (86) | 30 (86) |
| ≥PR | 47 (94) | 20 (100) | 20 (95) | 87 (96) | 34 (94) | 33 (94) |
High-risk patients are those with t(4;14) and/or del(17p) and/or add1q and/or ISS stage 3 disease. Standard-risk patients are all remaining patients, excluding 20 patients whose risk status was unknown.